New targets, drugs, and approaches for the treatment of cancer: An overview R.S. Kerbel OriginalPaper Pages: 145 - 147
An old paradigh for treating cancer and other diseases in the 21st century Thomas Boehm OriginalPaper Pages: 149 - 154
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy Larry WitteDaniel J. HicklinPeter Böhlen OriginalPaper Pages: 155 - 161
PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance Peter AtadjaToru WatanabeDalia Cohen OriginalPaper Pages: 163 - 168
The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target Christine BlancherAdrian L. Harris OriginalPaper Pages: 187 - 194
The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A Dihua YuMien-Chie Hung OriginalPaper Pages: 195 - 202
Pre-clinical development of farnesyltransferase inhibitors Robert B. LobellNancy E. Kohl OriginalPaper Pages: 203 - 210
Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies Lawrence D. Mayer OriginalPaper Pages: 211 - 218
Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance Rizwan HaqBrent Zanke OriginalPaper Pages: 233 - 239
The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities Gerhard SiemeisterGeorg Martiny-BaronDieter Marmé OriginalPaper Pages: 241 - 248
Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies David Spaner OriginalPaper Pages: 249 - 257
